Tingyuan (James) Xue

Prior Academic Affiliations: Southern Medical University

Thesis Mentor: David Horne, PhD & Elizabeth Budde, MD PhD

Thesis Title: Development of Novel Chimeric Antigen Receptor T Cells and Targets for Myeloid and Breast Malignancies

Fellowships, honors, awards etc:

Board Certification / Professional Membership: 

2014 – Present, People’s Republic of China Board Certification in Medicine

2019 – Present, Membership of American Society of Hematology (ASH)

Honors / Awards:

2010, Guangdong Provincial College Student Innovation Training Program

2013, National College Student Innovation Training Program

2015, “Climbing Project” Guangdong College Student Scientific Innovation Special Scholarship

2015, National Graduate Student Scholarship

2015, Grand Prize in 13th Guangdong Provincial “Challenge Cup” Competition of Science and Technology

2015, Grand Prize in 14th National “Challenge Cup” Competition of Science and Technology

2016, Deng, Xiaoping Science and Technology Innovation Team Leadership

2019, Graduate Student Travel Award by the IMGS of City of Hope

2019, International Young Investigator Award (YIA) by the Chinese American Hematologist and Oncologist Network (CAHON)

Publications:

Patents: 

a. Li Y, Xue T. (2017) Short peptide targeting EPS8 binding with EGFR and use thereof. Patent Number: US9828412B2. Date Issued: Nov. 28, 2017.

b. Li Y, Xue T. (2015) Oligopeptide formed by combining targeted EPS8 with EGFR and application of oligopeptide. Patent Number: CN103992382B. Date Issued: Mar. 11, 2015.

c. Xue T, Horne D, Budde L, Forman S. (2019) Targeting CD33 Using Chimeric Antigen Receptor T Cell Immunotherapy. Provisional Patent Application.

Peer-reviewed Publications:

a. Li Y*, Xue T (co-first author), He Y, Du J. (2013) Novel oncoprotein EPS8: a new target for anticancer therapy. Future Oncology (London, England). 9: 1587-94. 

b. Xue T, He Y, Zhang J, Zhang X, Xin Y, Lu Y, Li Y*. (2013) KIR2DL1-HLA signaling pathway: notable inhibition in the cytotoxicity of allo-NK cell against KG1A cell. Clinical Laboratory. 59: 613-9. 

c. Xue T, He Y, Lu Y, Zhang J, Zhang X, Xin Y, Li Y. (2011) The clinical application and research progress of allo-reactive NK cell in allo-HSCT. Medical Recapitulate. 17: 2244-6.

d. Chen Y, He Y, Lu X, Zeng Z, Tang C, Xue T* (co-corresponding author), Li Y*. (2015) Association between Fas/FasL polymorphism and susceptibility to leukemia: a meta-analysis. International Journal of Clinical and Experimental Medicine. 8(3):3817-24.

e. Li Y*, Zhou W, Du J, Jiang C, Xie X, Xue T, He Y. (2015) Generation of cytotoxic T lymphocytes specific for native or modified peptides derived from the epidermal growth factor receptor pathway substrate 8 antigen. Cancer Immunology, Immunotherapy. 64(2):259-69.

f. Xue T, Del Real M, Marcucci E, Toribio C, Setayesh M, Forman S, Horne D*, Budde L*. (2019) Hypomethylating Agent Potentiates CD33 Chimeric Antigen Receptor T Cell Therapy Against Acute Myeloid Leukemia. Clinical Cancer Research (In Preparation).

g. Xue T, Del Real M, Marcucci E, Toribio C, Setayesh M, Marcucci G, Forman S, Horne D*, Budde L*. (2019) Checkpoint Blockade in Combination with CD33 Chimeric Antigen Receptor T Cell Therapy and Hypomethylating Agent Against Acute Myeloid Leukemia. Blood 2019; 134 (Supplement_1): 1383 

h. Xue T, Budde L*. Immunotherapies Targeting CD123 for Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN), Hematol Oncol Clin North Am (June 2020, Invited Review). 

Oral & Poster Presentations: 

a. Xue T, Del Real M, Marcucci E, Toribio C, Setayesh M, Forman S, Horne D*, Budde L*. (2019) Checkpoint Blockade in Combination with CD33 Chimeric Antigen Receptor T Cell Therapy and Hypomethylating Agent Against Acute Myeloid Leukemia, Oral Presentation, 3rd Annual City of Hope Biomedical Research Graduate Student Symposium, Aug. 23, 2019; Duarte, CA.

b. Xue T, Del Real M, Toribio C, Setayesh M, Forman S, Horne D*, Budde L*. (2019) Targeting CD33 and C-Type Lectin-Like Molecule-1 (CLL-1) Using Chimeric Antigen Receptor (CAR) T Cell Therapies Confer Potent Antileukemic Responses for Acute Myeloid Leukemia (AML), Oral & Poster Presentations, 39th RSO Annual Advance Conference, Apr. 28-30, 2019; Lake Arrowhead, CA.

c. Xue T, Del Real M, Marcucci E, Toribio C, Setayesh M, Forman S, Horne D*, Budde L*. (2019) Checkpoint Blockade in Combination with CD33 Chimeric Antigen Receptor T Cell Therapy and Hypomethylating Agent Against Acute Myeloid Leukemia, 61st American Society of Hematology (ASH) Annual Meeting & Exposition, Dec. 7-10, 2019; Orlando, FL (Submitted).

d. Xue T, Lin M, Kowolik C, Yuan Y, Somlo G, Schmolze D, Riggs A, Horne D, Yadav S. (2018) Structural maintenance of chromosome 1A (SMC1A) as a novel target for triple-negative breast cancer (TNBC), City of Hope Annual Poster Session, Oct. 3, 2018; Duarte, CA.

e. Xue T, Lin M, Kowolik C, Yuan Y, Somlo G, Schmolze D, Riggs A, Horne D, Yadav S. (2018) Structural maintenance of chromosome 1A (SMC1A) as a novel target for triple-negative breast cancer (TNBC), Poster Presentation, 2nd Annual City of Hope Biomedical Research Graduate Student Symposium, Aug. 24, 2018; Duarte, CA.

f. Xue T, Chen Y, He Y, Lu X, Zeng Z, Tang C, Li Y. (2015) EPS8 as a new anticancer target in acute myeloid leukemia and a peptide inhibitor derived from the EGFR binding region of EPS8, Poster Presentation, AACR New Horizons in Cancer Research Conference: Bringing Cancer Discoveries to Patients, Nov. 12-15, 2015; Shanghai, China.

g. Del Real M, Setayesh M, Hernandez R, Toribio C, Chang W, Marcucci E, Xue T, Zain J, Rosen S, Forman S, Budde L. (2019) Targeting the chemokine receptor CCR4 using chimeric antigen receptor T cells for the treatment of CCR4+ T-cell malignancies, Oral & Poster Presentations, AACR Immune Cell Therapies for Cancer: Successes and Challenges of CAR T Cells and Other Forms of Adoptive Therapy, Jul. 19-22, 2019; San Francisco, CA.